End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Authors

Christopher Melani
Ranjana Advani
Mark Roschewski
Kelsey M. Walters
Clara C. Chen
Lucia Baratto
Mark A. Ahlman
Milos D. Miljkovic
Seth M Steinberg
Jessica Lam
Margaret Shovlin
Kieron Dunleavy, George Washington University
Stefania Pittaluga
Elaine S. Jaffe
Wyndham H. Wilson

Document Type

Journal Article

Publication Date

8-1-2018

Journal

Haematologica

Volume

103

Issue

8

Inclusive Pages

1337-1344

DOI

10.3324/haematol.2018.192492

Keywords

Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Middle Aged; Positron-Emission Tomography; Prednisone; Rituximab; Survival Analysis; Treatment Failure; Treatment Outcome; Vincristine; Young Adult

Comments

Epub 2018 May 10

APA Citation

Melani, C., Advani, R., Roschewski, M., Walters, K. M., Chen, C. C., Baratto, L., Ahlman, M. A., Miljkovic, M. D., Steinberg, S., Lam, J., Shovlin, M., Dunleavy, K., Pittaluga, S., Jaffe, E. S., & Wilson, W. H. (2018). End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.. Haematologica, 103 (8). http://dx.doi.org/10.3324/haematol.2018.192492

Peer Reviewed

1

Open Access

1